Editas Financial Statements From 2010 to 2026

Stocks . USA . 
Stock . Editas Medicine
EDIT Stock  USD 2.05  0.01  0.49%   
Analyzing historical trends in various income statement and balance sheet accounts from Editas Medicine's financial statements helps investors evaluate the company's valuation, profitability, and current liquidity needs. Key fundamental drivers impacting Editas Medicine's valuation are summarized below:
Gross Profit
-64.8 M
Market Capitalization
200.1 M
Enterprise Value Revenue
1.1669
Revenue
46.4 M
Earnings Share
(2.35)
There are currently one hundred twenty fundamental signals for Editas Medicine that can be evaluated and compared over time across rivals. All traders should verify Editas Medicine's prevailing fundamentals against the performance from 2010 to 2026 and make sure the trends continue to evolve in the right direction. Market Cap is likely to drop to about 89.4 M in 2026. Enterprise Value is likely to drop to about 6.9 M in 2026

Editas Medicine Total Revenue

32.03 Million

Check Editas Medicine financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Editas Medicine's main balance sheet or income statement drivers, such as Depreciation And Amortization of 3.5 M, Selling General Administrative of 55.2 M or Gross Profit of 39 M, as well as many indicators such as Price To Sales Ratio of 3.54, Dividend Yield of 0.0 or PTB Ratio of 0.74. Editas financial statements analysis is a perfect complement when working with Editas Medicine Valuation or Volatility modules.
  
Build AI portfolio with Editas Stock
Check out the analysis of Editas Medicine Correlation against competitors.
For more information on how to buy Editas Stock please use our How to Invest in Editas Medicine guide.

Editas Medicine Balance Sheet

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Total Assets394.2 M392.8 M299.7 M
Slightly volatile
Short and Long Term Debt Total36.2 M31.5 M36.3 M
Pretty Stable
Total Current Liabilities44.6 M88.8 M36.8 M
Slightly volatile
Other Liabilities71.4 M69.8 M53.6 M
Slightly volatile
Property Plant And Equipment Net36.4 M54.1 M28.7 M
Slightly volatile
Accounts Payable5.4 M6.3 M4.2 M
Slightly volatile
Cash146.7 M151.3 M112 M
Slightly volatile
Non Current Assets Total79.9 M60.1 M59.6 M
Slightly volatile
Non Currrent Assets Other4 M6 M3.2 M
Slightly volatile
Other Assets6.3 M6 M3 M
Slightly volatile
Cash And Short Term Investments305.8 M310.4 M232.8 M
Slightly volatile
Common Stock Shares Outstanding54.2 M94.7 M48.8 M
Slightly volatile
Liabilities And Stockholders Equity394.2 M392.8 M299.7 M
Slightly volatile
Non Current Liabilities Total117.5 M149.6 M91.5 M
Slightly volatile
Other Current Assets4.3 M3.6 M3.2 M
Slightly volatile
Total Liabilities162.1 M238.4 M128.3 M
Slightly volatile
Property Plant And Equipment Gross95 M90.5 M39.9 M
Slightly volatile
Total Current Assets314.3 M332.7 M240.1 M
Slightly volatile
Property Plant Equipment23.1 M17.9 M16.6 M
Slightly volatile
Current Deferred Revenue14 M12.9 M10.2 M
Slightly volatile
Long Term Debt28.6 M38.4 M23.9 M
Slightly volatile
Net Receivables19.6 M18.7 M4.9 M
Slightly volatile
Deferred Long Term Liabilities114.4 M108.9 M60.8 M
Slightly volatile
Short and Long Term Debt7.6 M8.6 M5.7 M
Slightly volatile
Short Term Debt11.3 M16.8 M8.3 M
Slightly volatile
Common Stock6.2 K9.2 K5.5 K
Slightly volatile
Capital Surpluse854.8 M1.7 B684.8 M
Slightly volatile
Common Stock Total Equity6 K8.1 K5.3 K
Slightly volatile
Long Term Debt Total26.9 M29.2 M33.1 M
Slightly volatile
Capital Lease Obligations36.4 M40.3 M34.4 M
Pretty Stable
Non Current Liabilities Other3.4 M3.5 M17.9 M
Slightly volatile
Net Invested Capital146.7 M154.4 M253.9 M
Pretty Stable
Net Working Capital264.6 M190.9 M304.1 M
Pretty Stable
Capital Stock7.2 K9.2 K6 K
Slightly volatile

Editas Medicine Income Statement

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Depreciation And Amortization3.5 M6.7 M2.8 M
Slightly volatile
Selling General Administrative55.2 M82.8 M44.2 M
Slightly volatile
Other Operating Expenses166.8 M326 M137 M
Slightly volatile
Research Development240.6 M229.1 M98.8 M
Slightly volatile
Cost Of Revenue5 M5.2 M32.3 M
Very volatile
Total Operating Expenses342.3 M326 M140.8 M
Slightly volatile
Interest Expense3 M4.9 M2.4 M
Slightly volatile
Interest Income17 M16.2 M4.9 M
Slightly volatile
Preferred Stock And Other Adjustments37.6 K42.3 K46.2 K
Slightly volatile
Reconciled Depreciation5 M6.7 M3.9 M
Slightly volatile

Editas Medicine Cash Flow Statement

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Stock Based Compensation21.5 M24.6 M16.5 M
Slightly volatile
Other Cashflows From Financing Activities40.2 M50.4 M42.3 M
Very volatile
Depreciation3.5 M6.7 M2.8 M
Slightly volatile
Capital Expenditures10.7 M10.1 M4.3 M
Slightly volatile
Total Cash From Financing Activities120.9 M64.4 M90.1 M
Slightly volatile
End Period Cash Flow149.3 M155.7 M114.8 M
Slightly volatile
Sale Purchase Of Stock1.4 M1.5 M37.9 M
Pretty Stable
Begin Period Cash Flow149.1 M146.7 M105.6 M
Slightly volatile
Change To Netincome36 M32.9 M25.2 M
Slightly volatile
Dividends Paid3.4 K3.6 K50.6 M
Slightly volatile

Financial Ratios

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Price To Sales Ratio3.543.72167
Slightly volatile
Days Sales Outstanding174165123
Slightly volatile
Stock Based Compensation To Revenue1.450.761.5386
Slightly volatile
Capex To Depreciation2.441.753.5079
Slightly volatile
EV To Sales0.270.29175
Slightly volatile
Payables Turnover1.161.227.5533
Pretty Stable
Sales General And Administrative To Revenue4.152.565.8812
Slightly volatile
Research And Ddevelopement To Revenue6.517.097.687
Slightly volatile
Capex To Revenue0.330.310.4718
Slightly volatile
Cash Per Share4.392.954.3209
Slightly volatile
Days Payables Outstanding326311181
Slightly volatile
Income Quality0.50.80.6109
Slightly volatile
Current Ratio8.224.316.1829
Pretty Stable
Receivables Turnover2.172.2878.8757
Very volatile
Capex Per Share0.120.10720.0958
Pretty Stable
Revenue Per Share0.420.350.3703
Slightly volatile
Interest Debt Per Share0.460.490.7414
Very volatile
Debt To Assets0.110.120.337
Slightly volatile
Days Of Payables Outstanding326311181
Slightly volatile
Ebt Per Ebit1.181.141.0677
Pretty Stable
Effective Tax Rate0.03950.06570.037
Slightly volatile
Quick Ratio8.334.316.2631
Slightly volatile
Net Income Per E B T0.810.910.9961
Slightly volatile
Cash Ratio1.861.963.5341
Very volatile
Days Of Sales Outstanding174165123
Slightly volatile
Free Cash Flow Operating Cash Flow Ratio1.211.21.1046
Pretty Stable
Fixed Asset Turnover0.660.620.7832
Pretty Stable
Debt Ratio0.110.120.337
Slightly volatile
Price Sales Ratio3.543.72167
Slightly volatile
Asset Turnover0.05410.08510.0512
Slightly volatile

Editas Medicine Valuation Data

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Market Cap89.4 M94.1 M868.7 M
Very volatile
Enterprise Value6.9 M7.3 M794.1 M
Very volatile

Editas Fundamental Market Drivers

Editas Upcoming Events

28th of February 2024
Upcoming Quarterly Report
View
3rd of May 2024
Next Financial Report
View
31st of December 2023
Next Fiscal Quarter End
View
28th of February 2024
Next Fiscal Year End
View
30th of September 2023
Last Quarter Report
View
31st of December 2022
Last Financial Announcement
View

About Editas Medicine Financial Statements

Editas Medicine shareholders use historical fundamental indicators, such as revenue or net income, to determine how well the company is positioned to perform in the future. Although Editas Medicine investors may analyze each financial statement separately, they are all interrelated. The changes in Editas Medicine's assets and liabilities, for example, are also reflected in the revenues and expenses on on Editas Medicine's income statement. Understanding these patterns can help investors time the market effectively. Please read more on our fundamental analysis page.
Last ReportedProjected for Next Year
Current Deferred Revenue12.9 M14 M
Cost Of Revenue5.2 M5 M
Total Revenue37.2 M32 M
Stock Based Compensation To Revenue 0.76  1.45 
Sales General And Administrative To Revenue 2.56  4.15 
Research And Ddevelopement To Revenue 7.09  6.51 
Capex To Revenue 0.31  0.33 
Revenue Per Share 0.35  0.42 
Ebit Per Revenue(6.65)(6.99)

Thematic Opportunities

Explore Investment Opportunities

Build portfolios using Macroaxis predefined set of investing ideas. Many of Macroaxis investing ideas can easily outperform a given market. Ideas can also be optimized per your risk profile before portfolio origination is invoked. Macroaxis thematic optimization helps investors identify companies most likely to benefit from changes or shifts in various micro-economic or local macro-level trends. Originating optimal thematic portfolios involves aligning investors' personal views, ideas, and beliefs with their actual investments.
Explore Investing Ideas  

Additional Tools for Editas Stock Analysis

When running Editas Medicine's price analysis, check to measure Editas Medicine's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Editas Medicine is operating at the current time. Most of Editas Medicine's value examination focuses on studying past and present price action to predict the probability of Editas Medicine's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Editas Medicine's price. Additionally, you may evaluate how the addition of Editas Medicine to your portfolios can decrease your overall portfolio volatility.
Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions
 
Feedback Blog
Made with optimal in San Francisco
2026 Macroaxis LLC
COMMON DESTINATIONS
MAIN CATEGORIES
COMPANY